Discovery of novel vaccine candidates based on the immunogenic epitopes derived from Toxoplasma membrane proteins.

IF 2.1 Q4 IMMUNOLOGY Clinical and Experimental Vaccine Research Pub Date : 2025-01-01 Epub Date: 2025-01-13 DOI:10.7774/cevr.2025.14.e4
Seyyed Amir Hosseini, Saman Hashemi, Davood Siamian, Ali Asghari, Mohammad Fathollahzadeh, Hamidreza Majidiani, Iman Shahraki, Mohamad Hosein Safari
{"title":"Discovery of novel vaccine candidates based on the immunogenic epitopes derived from <i>Toxoplasma</i> membrane proteins.","authors":"Seyyed Amir Hosseini, Saman Hashemi, Davood Siamian, Ali Asghari, Mohammad Fathollahzadeh, Hamidreza Majidiani, Iman Shahraki, Mohamad Hosein Safari","doi":"10.7774/cevr.2025.14.e4","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Due to the widespread distribution and importance of <i>Toxoplasma gondii</i> infection as a parasitic zoonosis, multi-epitope vaccine design was implemented using a set of immunodominant epitopes screened out of a wide scope of membrane proteins.</p><p><strong>Materials and methods: </strong>On this basis, 5 vaccine candidates were created using linkers ([GGGGS]<sub>2</sub>, KK, AAY, GPGPG, GDGDG, EAAAK) and adjuvants (RS-09 peptide, <i>Mycobacterium tuberculosis</i> resuscitation-promoting factor E [RpfE] and 50S ribosomal protein, human interferon [IFN]-γ).</p><p><strong>Results: </strong>Polytopes with RS-09 alone (Toxo-App) and with IFN-γ (Toxo-Apfn), and one with 50S ribosomal protein (Toxo-Ribos) showed the highest immunogenicity during <i>in silico</i> prediction, and their 3-dimensional structure was refined. Protein-protein docking and molecular dynamics simulation analysis was done between the Toxo-App and human toll-like receptor (TLR)-4, rendering a stable connection. Codon optimization and <i>in silico</i> cloning was done ultimately for the selected vaccine candidate.</p><p><strong>Conclusion: </strong>In conclusion, potent multi-epitope vaccine candidates were designed against toxoplasmosis using a diverse set of <i>in silico</i> techniques, while further wet experiments are recommended.</p>","PeriodicalId":51768,"journal":{"name":"Clinical and Experimental Vaccine Research","volume":"14 1","pages":"86-100"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11799584/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Vaccine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7774/cevr.2025.14.e4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/13 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Due to the widespread distribution and importance of Toxoplasma gondii infection as a parasitic zoonosis, multi-epitope vaccine design was implemented using a set of immunodominant epitopes screened out of a wide scope of membrane proteins.

Materials and methods: On this basis, 5 vaccine candidates were created using linkers ([GGGGS]2, KK, AAY, GPGPG, GDGDG, EAAAK) and adjuvants (RS-09 peptide, Mycobacterium tuberculosis resuscitation-promoting factor E [RpfE] and 50S ribosomal protein, human interferon [IFN]-γ).

Results: Polytopes with RS-09 alone (Toxo-App) and with IFN-γ (Toxo-Apfn), and one with 50S ribosomal protein (Toxo-Ribos) showed the highest immunogenicity during in silico prediction, and their 3-dimensional structure was refined. Protein-protein docking and molecular dynamics simulation analysis was done between the Toxo-App and human toll-like receptor (TLR)-4, rendering a stable connection. Codon optimization and in silico cloning was done ultimately for the selected vaccine candidate.

Conclusion: In conclusion, potent multi-epitope vaccine candidates were designed against toxoplasmosis using a diverse set of in silico techniques, while further wet experiments are recommended.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.70
自引率
3.70%
发文量
29
审稿时长
8 weeks
期刊介绍: Clin Exp Vaccine Res, the official English journal of the Korean Vaccine Society, is an international, peer reviewed, and open-access journal. It covers all areas related to vaccines and vaccination. Clin Exp Vaccine Res publishes editorials, review articles, special articles, original articles, case reports, brief communications, and correspondences covering a wide range of clinical and experimental subjects including vaccines and vaccination for human and animals against infectious diseases caused by viruses, bacteria, parasites and tumor. The scope of the journal is to disseminate information that may contribute to elaborate vaccine development and vaccination strategies targeting infectious diseases and tumors in human and animals. Relevant topics range from experimental approaches to (pre)clinical trials for the vaccine research based on, but not limited to, basic laboratory, translational, and (pre)clinical investigations, epidemiology of infectious diseases and progression of all aspects in the health related issues. It is published printed and open accessed online issues (https://ecevr.org) two times per year in 31 January and 31 July. Clin Exp Vaccine Res is linked to many international databases and is made freely available to institutions and individuals worldwide
期刊最新文献
Impact of COVID-19 vaccination on lower urinary tract (LUTS) in benign prostatic hyperplasia (BPH) patients. Root causes of low influenza vaccination coverage rates among nurses working in a tertiary care university hospital in Turkey: result of a study using nominal group technique. Safety and immunogenicity of an inactivated vero cell-based rabies vaccine (Rabivax-S) in pre-exposure prophylaxis schedule in Vietnam. Vaccination status of elite athletes in the German Armed Forces: a retrospective descriptive overview. A comparison between adjuvant and delivering functions of iron oxide and calcium phosphate nanoparticles, using a model protein against Brucella melitensis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1